Stockreport

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Gyre Therapeutics, Inc.  (GYRE) 
PDF U.S. IND submission to evaluate F351 for the treatment of NASH-associated liver fibrosis expected in late 2024; Phase 2a trial expected to initiate in 2025 Acquired t [Read more]